{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:38:31Z","timestamp":1793425111462,"version":"4.5.0"},"reference-count":161,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900775"],"award-info":[{"award-number":["81900775"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.bbrc.2025.151498","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T07:19:01Z","timestamp":1739776741000},"page":"151498","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Mitochondrial targeted therapies in MAFLD"],"prefix":"10.1016","volume":"753","author":[{"given":"Sien","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2025.151498_bib1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2025.151498_bib2","doi-asserted-by":"crossref","DOI":"10.1177\/20420188221145549","article-title":"MAFLD: a multisystem disease","volume":"14","author":"Pipitone","year":"2023","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.bbrc.2025.151498_bib3","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2025.151498_bib4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2025.151498_bib5","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2025.151498_bib6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.metabol.2017.11.003","article-title":"Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis","volume":"79","author":"Mantovani","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.bbrc.2025.151498_bib7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbrc.2025.151498_bib8","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.bbrc.2025.151498_bib9","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.bbrc.2025.151498_bib10","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2025.151498_bib11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.biocel.2017.12.019","article-title":"Mitochondria in non-alcoholic fatty liver disease","volume":"95","author":"Simoes","year":"2018","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.bbrc.2025.151498_bib12","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/hep.26226","article-title":"Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease","volume":"58","author":"Begriche","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2025.151498_bib13","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.bbrc.2025.151498_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.80","article-title":"Nonalcoholic fatty liver disease","volume":"1","author":"Brunt","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bbrc.2025.151498_bib15","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"N. Nonalcoholic Steatohepatitis Clinical Research, Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2025.151498_bib16","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(14)60121-5","article-title":"Liver cirrhosis","volume":"383","author":"Tsochatzis","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2025.151498_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156028","article-title":"The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: an international multidisciplinary expert consensus","volume":"161","author":"Zeng","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.bbrc.2025.151498_bib18","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jhep.2018.01.019","article-title":"Fructose and sugar: a major mediator of non-alcoholic fatty liver disease","volume":"68","author":"Jensen","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2025.151498_bib19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","article-title":"Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases","volume":"27","author":"Samuel","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbrc.2025.151498_bib20","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease","volume":"75","author":"Ipsen","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bbrc.2025.151498_bib21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1089\/ars.2016.6776","article-title":"Oxidative stress as a critical factor in nonalcoholic fatty liver disease pathogenesis","volume":"26","author":"Spahis","year":"2017","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.bbrc.2025.151498_bib22","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1007\/s10620-016-4049-x","article-title":"Innate immunity and inflammation in NAFLD\/NASH","volume":"61","author":"Arrese","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.bbrc.2025.151498_bib23","doi-asserted-by":"crossref","first-page":"6184","DOI":"10.3390\/ijms15046184","article-title":"Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease","volume":"15","author":"Jung","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2025.151498_bib24","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbrc.2025.151498_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/antiox12040833","article-title":"Mediterranean diet improves plasma biomarkers related to oxidative stress and inflammatory process in patients with non-alcoholic fatty liver disease","volume":"12","author":"Quetglas-Llabres","year":"2023","journal-title":"Antioxidants"},{"key":"10.1016\/j.bbrc.2025.151498_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/antiox12081554","article-title":"Plasma fatty acid composition, oxidative and inflammatory status, and adherence to the mediterranean diet of patients with non-alcoholic fatty liver disease","volume":"12","author":"Monserrat-Mesquida","year":"2023","journal-title":"Antioxidants"},{"key":"10.1016\/j.bbrc.2025.151498_bib27","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nrgastro.2016.85","article-title":"The role of the gut microbiota in NAFLD","volume":"13","author":"Leung","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbrc.2025.151498_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/nu11030677","article-title":"Impact of nutritional changes on nonalcoholic fatty liver disease","volume":"11","author":"Perdomo","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.bbrc.2025.151498_bib29","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbrc.2025.151498_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mito.2005.10.004","article-title":"Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it","volume":"6","author":"Begriche","year":"2006","journal-title":"Mitochondrion"},{"key":"10.1016\/j.bbrc.2025.151498_bib31","doi-asserted-by":"crossref","first-page":"8713","DOI":"10.3390\/ijms15058713","article-title":"Role of mitochondria in nonalcoholic fatty liver disease","volume":"15","author":"Nassir","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2025.151498_bib32","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.bi.49.070180.002143","article-title":"Regulation of hepatic fatty acid oxidation and ketone body production","volume":"49","author":"McGarry","year":"1980","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bbrc.2025.151498_bib33","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1152\/physrev.1990.70.3.701","article-title":"Nitrogen metabolism and ornithine cycle function","volume":"70","author":"Meijer","year":"1990","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bbrc.2025.151498_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20081386","article-title":"How mitochondria produce reactive oxygen species","volume":"417","author":"Murphy","year":"2009","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbrc.2025.151498_bib35","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrm3412","article-title":"Mitochondria as sensors and regulators of calcium signalling","volume":"13","author":"Rizzuto","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbrc.2025.151498_bib36","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3748\/wjg.14.193","article-title":"Nonalcoholic fatty liver disease and mitochondrial dysfunction","volume":"14","author":"Wei","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbrc.2025.151498_bib37","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.dld.2020.04.019","article-title":"Suppression of high-fat diet-induced obesity-associated liver mitochondrial dysfunction by docosahexaenoic acid and hydroxytyrosol co-administration","volume":"52","author":"Ortiz","year":"2020","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.bbrc.2025.151498_bib38","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1039\/C9FO01373C","article-title":"High-fat diet induces mouse liver steatosis with a concomitant decline in energy metabolism: attenuation by eicosapentaenoic acid (EPA) or hydroxytyrosol (HT) supplementation and the additive effects upon EPA and HT co-administration","volume":"10","author":"Echeverria","year":"2019","journal-title":"Food Funct."},{"key":"10.1016\/j.bbrc.2025.151498_bib39","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/hep.1840380426","article-title":"Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis","volume":"38","author":"Perez-Carreras","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2025.151498_bib40","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cmet.2015.04.004","article-title":"Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis","volume":"21","author":"Koliaki","year":"2015","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbrc.2025.151498_bib41","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/gut.2007.147496","article-title":"Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia-reperfusion injury","volume":"57","author":"Serviddio","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.bbrc.2025.151498_bib42","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jhep.2005.03.004","article-title":"NASH: a mitochondrial disease","volume":"42","author":"Pessayre","year":"2005","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2025.151498_bib43","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S0168-8278(99)80033-6","article-title":"Mitochondrial abnormalities in non-alcoholic steatohepatitis","volume":"31","author":"Caldwell","year":"1999","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2025.151498_bib44","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1017\/S0007114511000493","article-title":"Mitochondrial dysfunction in the liver of type 2 diabetic Goto-Kakizaki rats: improvement by a combination of nutrients","volume":"106","author":"Hao","year":"2011","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.bbrc.2025.151498_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.162","article-title":"Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD","volume":"5","author":"Gonzalez-Rodriguez","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbrc.2025.151498_bib46","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1053\/gast.2001.23256","article-title":"Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities","volume":"120","author":"Sanyal","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbrc.2025.151498_bib47","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1053\/j.gastro.2005.02.001","article-title":"Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance","volume":"128","author":"Ibdah","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbrc.2025.151498_bib48","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cmet.2006.07.006","article-title":"Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis","volume":"4","author":"Mari","year":"2006","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbrc.2025.151498_bib49","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2009.11.030","article-title":"Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model","volume":"52","author":"Rector","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2025.151498_bib50","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1172\/JCI83885","article-title":"Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9","volume":"126","author":"Garcia-Martinez","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bbrc.2025.151498_bib51","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.abb.2014.02.015","article-title":"Cellular and molecular mechanisms in liver fibrogenesis","volume":"548","author":"Novo","year":"2014","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbrc.2025.151498_bib52","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1478-3231.2012.02775.x","article-title":"Oxidative stress rather than triglyceride accumulation is a determinant of mitochondrial dysfunction in in vitro models of hepatic cellular steatosis","volume":"32","author":"Lockman","year":"2012","journal-title":"Liver Int."},{"key":"10.1016\/j.bbrc.2025.151498_bib53","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0016-5085(03)00907-7","article-title":"Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis","volume":"125","author":"Feldstein","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbrc.2025.151498_bib54","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.freeradbiomed.2007.12.029","article-title":"Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases","volume":"44","author":"Mantena","year":"2008","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bbrc.2025.151498_bib55","doi-asserted-by":"crossref","first-page":"14205","DOI":"10.3748\/wjg.v20.i39.14205","article-title":"Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease","volume":"20","author":"Paradies","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbrc.2025.151498_bib56","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/nm.3735","article-title":"Chronic enrichment of hepatic endoplasmic reticulum-mitochondria contact leads to mitochondrial dysfunction in obesity","volume":"20","author":"Arruda","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.bbrc.2025.151498_bib57","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.bbrc.2025.151498_bib58","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/liv.15930","article-title":"The first MASH drug therapy on the horizon: current perspectives of resmetirom","volume":"44","author":"Petta","year":"2024","journal-title":"Liver Int."},{"key":"10.1016\/j.bbrc.2025.151498_bib59","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1007\/s10620-016-4054-0","article-title":"Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease","volume":"61","author":"Softic","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.bbrc.2025.151498_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.796207","article-title":"Mitochondrial targeting therapeutics: promising role of natural products in non-alcoholic fatty liver disease","volume":"12","author":"Xu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.151498_bib61","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1139\/h11-076","article-title":"Skeletal muscle and beyond: the role of exercise as a mediator of systemic mitochondrial biogenesis","volume":"36","author":"Little","year":"2011","journal-title":"Appl Physiol Nutr Metab"},{"key":"10.1016\/j.bbrc.2025.151498_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molmet.2019.11.015","article-title":"Physical exercise and liver \"fitness\": role of mitochondrial function and epigenetics-related mechanisms in non-alcoholic fatty liver disease","volume":"32","author":"Stevanovic","year":"2020","journal-title":"Mol Metab"},{"key":"10.1016\/j.bbrc.2025.151498_bib63","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.mito.2013.07.002","article-title":"Modulation of hepatic redox status and mitochondrial metabolism by exercise: therapeutic strategy for liver diseases","volume":"13","author":"Ascensao","year":"2013","journal-title":"Mitochondrion"},{"key":"10.1016\/j.bbrc.2025.151498_bib64","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1113\/jphysiol.2008.156745","article-title":"Cessation of daily exercise dramatically alters precursors of hepatic steatosis in Otsuka Long-Evans Tokushima Fatty (OLETF) rats","volume":"586","author":"Rector","year":"2008","journal-title":"J. Physiol."},{"key":"10.1016\/j.bbrc.2025.151498_bib65","doi-asserted-by":"crossref","first-page":"G619","DOI":"10.1152\/ajpgi.00428.2007","article-title":"Daily exercise increases hepatic fatty acid oxidation and prevents steatosis in Otsuka Long-Evans Tokushima Fatty rats","volume":"294","author":"Rector","year":"2008","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbrc.2025.151498_bib66","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1113\/JP278853","article-title":"Exercise and mitochondrial health","volume":"599","author":"Memme","year":"2021","journal-title":"J. Physiol."},{"key":"10.1016\/j.bbrc.2025.151498_bib67","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.molmet.2018.10.005","article-title":"Moderate weight loss attenuates chronic endoplasmic reticulum stress and mitochondrial dysfunction in human obesity","volume":"19","author":"Lopez-Domenech","year":"2019","journal-title":"Mol Metab"},{"key":"10.1016\/j.bbrc.2025.151498_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155937","article-title":"Obesity and MASLD: is weight loss the (only) key to treat metabolic liver disease?","volume":"157","author":"Huttasch","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.bbrc.2025.151498_bib69","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.2337\/dc10-0856","article-title":"Liver Subgroup of the Look, Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes","volume":"33","author":"Lazo","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bbrc.2025.151498_bib70","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2025.151498_bib71","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.cgh.2017.04.016","article-title":"A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis","volume":"15","author":"Wah Kheong","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbrc.2025.151498_bib72","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/9233650","article-title":"A molecular insight into the role of antioxidants in nonalcoholic fatty liver diseases","volume":"2022","author":"Ezhilarasan","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.bbrc.2025.151498_bib73","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.apsb.2018.05.006","article-title":"Mitochondria-targeting drug conjugates for cytotoxic, anti-oxidizing and sensing purposes: current strategies and future perspectives","volume":"8","author":"Battogtokh","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bbrc.2025.151498_bib74","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jhep.2009.02.023","article-title":"Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells","volume":"50","author":"Trappoliere","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2025.151498_bib75","first-page":"9","article-title":"Silymarin in treatment of non-alcoholic steatohepatitis: a randomized clinical trial","volume":"5","author":"Solhi","year":"2014","journal-title":"Caspian J Intern Med"},{"key":"10.1016\/j.bbrc.2025.151498_bib76","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1074\/jbc.M009093200","article-title":"Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties","volume":"276","author":"Kelso","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2025.151498_bib77","doi-asserted-by":"crossref","first-page":"21295","DOI":"10.1074\/jbc.M501527200","article-title":"Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools","volume":"280","author":"James","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2025.151498_bib78","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.bbadis.2005.10.007","article-title":"Targeting antioxidants to mitochondria: a new therapeutic direction","volume":"1762","author":"Sheu","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbrc.2025.151498_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2020.08.008","article-title":"Vitamin E in paediatric non-alcoholic fatty liver disease: a meta-analysis","volume":"45","author":"Lin","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.bbrc.2025.151498_bib80","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1096\/fj.03-0240fje","article-title":"Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants","volume":"17","author":"Jauslin","year":"2003","journal-title":"FASEB J."},{"key":"10.1016\/j.bbrc.2025.151498_bib81","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.3945\/jn.110.121715","article-title":"A mitochondria-targeted vitamin E derivative decreases hepatic oxidative stress and inhibits fat deposition in mice","volume":"140","author":"Mao","year":"2010","journal-title":"J. Nutr."},{"key":"10.1016\/j.bbrc.2025.151498_bib82","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9329427","article-title":"Protective effects of MitoTEMPO on nonalcoholic fatty liver disease via regulating myeloid-derived suppressor cells and inflammation in mice","volume":"2020","author":"Wu","year":"2020","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.bbrc.2025.151498_bib83","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nature16969","article-title":"NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis","volume":"531","author":"Ma","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2025.151498_bib84","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.mito.2021.02.007","article-title":"Protective effects of a mitochondria-targeted small peptide SS31 against hyperglycemia-induced mitochondrial abnormalities in the liver tissues of diabetic mice, Tallyho\/JngJ mice","volume":"58","author":"Bhatti","year":"2021","journal-title":"Mitochondrion"},{"key":"10.1016\/j.bbrc.2025.151498_bib85","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1126\/science.1218530","article-title":"Identification and functional expression of the mitochondrial pyruvate carrier","volume":"337","author":"Herzig","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2025.151498_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/biom13020261","article-title":"The hepatic mitochondrial pyruvate carrier as a regulator of systemic metabolism and a therapeutic target for treating metabolic disease","volume":"13","author":"McCommis","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.bbrc.2025.151498_bib87","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1128\/MCB.00166-16","article-title":"Requirement for the mitochondrial pyruvate carrier in mammalian development revealed by a hypomorphic allelic series","volume":"36","author":"Bowman","year":"2016","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.bbrc.2025.151498_bib88","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.cmet.2015.07.028","article-title":"Loss of mitochondrial pyruvate carrier 2 in the liver leads to defects in gluconeogenesis and compensation via pyruvate-alanine cycling","volume":"22","author":"McCommis","year":"2015","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbrc.2025.151498_bib89","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/hep.29025","article-title":"Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis","volume":"65","author":"McCommis","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2025.151498_bib90","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/13543784.2018.1494153","article-title":"MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis","volume":"27","author":"Colca","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.bbrc.2025.151498_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101178","article-title":"Therapeutic potential of mitochondrial uncouplers for the treatment of metabolic associated fatty liver disease and NASH","volume":"46","author":"Goedeke","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.bbrc.2025.151498_bib92","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2025.151498_bib93","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.cmet.2020.04.011","article-title":"Low-dose sorafenib acts as a mitochondrial uncoupler and ameliorates nonalcoholic steatohepatitis","volume":"31","author":"Jian","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbrc.2025.151498_bib94","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-152-6-201003160-00004","article-title":"The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial","volume":"152","author":"Goldfine","year":"2010","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bbrc.2025.151498_bib95","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1345\/aph.1M483","article-title":"Potential role of salicylates in type 2 diabetes","volume":"44","author":"Rumore","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.bbrc.2025.151498_bib96","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.2337\/dc13-0859","article-title":"Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD)","volume":"36","author":"Goldfine","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bbrc.2025.151498_bib97","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.1111\/bph.13315","article-title":"Salsalate attenuates diet induced non-alcoholic steatohepatitis in mice by decreasing lipogenic and inflammatory processes","volume":"172","author":"Liang","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.151498_bib98","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bcpt.13535","article-title":"Salsalate reverses metabolic disorders in a mouse model of non-alcoholic fatty liver disease through AMPK activation and caspase-6 activity inhibition","volume":"128","author":"Li","year":"2021","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.bbrc.2025.151498_bib99","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.2337\/db16-0564","article-title":"Salsalate (salicylate) uncouples mitochondria, improves glucose homeostasis, and reduces liver lipids independent of AMPK-beta1","volume":"65","author":"Smith","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.bbrc.2025.151498_bib100","doi-asserted-by":"crossref","first-page":"15731","DOI":"10.1074\/jbc.M117.791863","article-title":"The unintended mitochondrial uncoupling effects of the FDA-approved anti-helminth drug nitazoxanide mitigates experimental parkinsonism in mice","volume":"292","author":"Amireddy","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2025.151498_bib101","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cellsig.2017.04.001","article-title":"Niclosamide: beyond an antihelminthic drug","volume":"41","author":"Chen","year":"2018","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bbrc.2025.151498_bib102","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/2211016a0","article-title":"Mechanism of action of reagents that uncouple oxidative phosphorylation","volume":"221","author":"Weinbach","year":"1969","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2025.151498_bib103","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1126\/science.158.3809.1694","article-title":"Salicylanilides: a new group of active uncouplers of oxidative phosphorylation","volume":"158","author":"Williamson","year":"1967","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2025.151498_bib104","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12902-022-01046-y","article-title":"Association between type 2 diabetes status and prevalence of liver steatosis and fibrosis among adults aged >\/= 40 years","volume":"22","author":"Chen","year":"2022","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.bbrc.2025.151498_bib105","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11020073","article-title":"Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.bbrc.2025.151498_bib106","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1001\/jama.2019.3805","article-title":"Metformin in 2019","volume":"321","author":"Flory","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.bbrc.2025.151498_bib107","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.celrep.2019.09.070","article-title":"Metformin improves mitochondrial respiratory activity through activation of AMPK","volume":"29","author":"Wang","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbrc.2025.151498_bib108","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.biopha.2019.01.021","article-title":"Metformin enhances mitochondrial biogenesis and thermogenesis in brown adipocytes of mice","volume":"111","author":"Karise","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbrc.2025.151498_bib109","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cell.2009.03.016","article-title":"Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein","volume":"137","author":"He","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2025.151498_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120956","article-title":"Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms","volume":"308","author":"Shaaban","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.bbrc.2025.151498_bib111","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrendo.2016.135","article-title":"PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD","volume":"13","author":"Gross","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bbrc.2025.151498_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.615409","article-title":"Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis","volume":"12","author":"Lian","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.bbrc.2025.151498_bib113","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/hep4.1723","article-title":"Deuterium-Stabilized (R)-Pioglitazone (PXL065) is responsible for pioglitazone efficacy in NASH yet exhibits little to No PPARgamma activity","volume":"5","author":"Jacques","year":"2021","journal-title":"Hepatol Commun"},{"issue":"Suppl 1","key":"10.1016\/j.bbrc.2025.151498_bib114","doi-asserted-by":"crossref","first-page":"2S28","DOI":"10.1016\/S1262-3636(17)30070-8","article-title":"GLP-1 receptor agonists in NAFLD","volume":"43","author":"Petit","year":"2017","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.bbrc.2025.151498_bib115","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1210\/clinem\/dgab578","article-title":"The emerging role of glucagon-like peptide-1 receptor agonists for the management of NAFLD","volume":"107","author":"Patel Chavez","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bbrc.2025.151498_bib116","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/dom.14565","article-title":"Effects of glucagon-like peptide-1 receptor agonists on histopathological and secondary biomarkers of non-alcoholic steatohepatitis: a systematic review and meta-analysis","volume":"24","author":"Borodavkin","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bbrc.2025.151498_bib117","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fcvm.2019.00186","article-title":"SGLT2 inhibitors play a salutary role in heart failure via modulation of the mitochondrial function","volume":"6","author":"Maejima","year":"2019","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.bbrc.2025.151498_bib118","doi-asserted-by":"crossref","first-page":"F767","DOI":"10.1152\/ajprenal.00565.2018","article-title":"Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy","volume":"317","author":"Lee","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.bbrc.2025.151498_bib119","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/toxsci\/57.1.177","article-title":"Bile acids affect liver mitochondrial bioenergetics: possible relevance for cholestasis therapy","volume":"57","author":"Rolo","year":"2000","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.bbrc.2025.151498_bib120","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/hep.29359","article-title":"The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids","volume":"67","author":"Puri","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2025.151498_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103290","article-title":"Conjugated secondary 12alpha-hydroxylated bile acids promote liver fibrogenesis","volume":"66","author":"Xie","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bbrc.2025.151498_bib122","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1007\/s10620-015-3776-8","article-title":"Altered bile acid metabolome in patients with nonalcoholic steatohepatitis","volume":"60","author":"Ferslew","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.bbrc.2025.151498_bib123","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41401-022-00880-z","article-title":"Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease","volume":"43","author":"Jiao","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bbrc.2025.151498_bib124","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2015.12.007","article-title":"Pharmacology of bile acid receptors: evolution of bile acids from simple detergents to complex signaling molecules","volume":"104","author":"Copple","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbrc.2025.151498_bib125","doi-asserted-by":"crossref","DOI":"10.3390\/biom8040159","article-title":"Overview of bile acids signaling and perspective on the signal of ursodeoxycholic acid, the most hydrophilic bile acid, in the heart","volume":"8","author":"Hanafi","year":"2018","journal-title":"Biomolecules"},{"key":"10.1016\/j.bbrc.2025.151498_bib126","first-page":"471","article-title":"Toxicity of bile acids on the electron transport chain of isolated rat liver mitochondria","volume":"19","author":"Krahenbuhl","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2025.151498_bib127","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/1744666X.2017.1391093","article-title":"From pathogenesis to novel therapies in the treatment of primary biliary cholangitis","volume":"13","author":"Ronca","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.bbrc.2025.151498_bib128","article-title":"Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1\/FXR signaling","volume":"1867","author":"Marchiano","year":"2022","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.bbrc.2025.151498_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.174760","article-title":"Ursodesoxycholic acid is an FFA4 agonist and reduces hepatic steatosis via FFA4 signaling","volume":"917","author":"Xu","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.151498_bib130","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41598-023-28647-4","article-title":"Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH","volume":"13","author":"Marchiano","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2025.151498_bib131","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.bbrc.2020.05.128","article-title":"Ursodeoxycholic acid alleviates nonalcoholic fatty liver disease by inhibiting apoptosis and improving autophagy via activating AMPK","volume":"529","author":"Wu","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2025.151498_bib132","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1042\/CS20110184","article-title":"Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications","volume":"121","author":"Roma","year":"2011","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.bbrc.2025.151498_bib133","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.jhep.2014.12.034","article-title":"Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity","volume":"62","author":"Mueller","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2025.151498_bib134","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/liv.13562","article-title":"Ursodeoxycholic acid: effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients","volume":"38","author":"Mueller","year":"2018","journal-title":"Liver Int."},{"key":"10.1016\/j.bbrc.2025.151498_bib135","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2468-1253(19)30184-0","article-title":"Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial","volume":"4","author":"Traussnigg","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.bbrc.2025.151498_bib136","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1038\/s41467-021-25701-5","article-title":"A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes","volume":"12","author":"Harrison","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2025.151498_bib137","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/bmb\/ldaa006","article-title":"Obeticholic acid-a new therapy in PBC and NASH","volume":"133","author":"Chapman","year":"2020","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.bbrc.2025.151498_bib138","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2025.151498_bib139","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2021.10.029","article-title":"Non-invasive evaluation of response to obeticholic acid in patients with NASH: results from the REGENERATE study","volume":"76","author":"Rinella","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2025.151498_bib140","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/00007890-196803000-00009","article-title":"Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues","volume":"6","author":"Friedenstein","year":"1968","journal-title":"Transplantation"},{"key":"10.1016\/j.bbrc.2025.151498_bib141","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41423-023-00983-5","article-title":"Mesenchymal stromal cells in hepatic fibrosis\/cirrhosis: from pathogenesis to treatment","volume":"20","author":"Yang","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bbrc.2025.151498_bib142","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13287-019-1260-7","article-title":"Mesenchymal stem cells overexpressing hepatocyte nuclear factor-4 alpha alleviate liver injury by modulating anti-inflammatory functions in mice","volume":"10","author":"Ye","year":"2019","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.bbrc.2025.151498_bib143","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/1526217","article-title":"Advance of mesenchymal stem cells in chronic end-stage liver disease control","volume":"2022","author":"Gao","year":"2022","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.bbrc.2025.151498_bib144","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13287-018-0816-2","article-title":"A pooled analysis of mesenchymal stem cell-based therapy for liver disease","volume":"9","author":"Zhao","year":"2018","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.bbrc.2025.151498_bib145","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/stem.632","article-title":"Human mesenchymal stem cells reprogram adult cardiomyocytes toward a progenitor-like state through partial cell fusion and mitochondria transfer","volume":"29","author":"Acquistapace","year":"2011","journal-title":"Stem Cell."},{"key":"10.1016\/j.bbrc.2025.151498_bib146","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.stemcr.2016.08.009","article-title":"iPSC-MSCs with high intrinsic MIRO1 and sensitivity to TNF-alpha yield efficacious mitochondrial transfer to rescue anthracycline-induced cardiomyopathy","volume":"7","author":"Zhang","year":"2016","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.bbrc.2025.151498_bib147","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1186\/s13287-021-02663-5","article-title":"Bone marrow derived-mesenchymal stem cell improves diabetes-associated fatty liver via mitochondria transformation in mice","volume":"12","author":"Bi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.bbrc.2025.151498_bib148","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1042\/CBI20110634","article-title":"Mesenchymal stem cells restore CCl4-induced liver injury by an antioxidative process","volume":"36","author":"Cho","year":"2012","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.bbrc.2025.151498_bib149","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6079642","article-title":"Human umbilical cord MSC-derived exosomes suppress the development of CCl(4)-induced liver injury through antioxidant effect","volume":"2018","author":"Jiang","year":"2018","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.bbrc.2025.151498_bib150","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1111\/jcmm.16338","article-title":"Mesenchymal stromal cells protect hepatocytes from lipotoxicity through alleviation of endoplasmic reticulum stress by restoring SERCA activity","volume":"25","author":"Li","year":"2021","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.bbrc.2025.151498_bib151","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/HYPERTENSIONAHA.117.10787","article-title":"Chronic supplementation with a mitochondrial antioxidant (MitoQ) improves vascular function in healthy older adults","volume":"71","author":"Rossman","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.bbrc.2025.151498_bib152","doi-asserted-by":"crossref","first-page":"e1212","DOI":"10.1212\/WNL.0000000000005255","article-title":"Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy","volume":"90","author":"Karaa","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.bbrc.2025.151498_bib153","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1055\/s-0028-1128142","article-title":"Improvement of insulin sensitivity by a novel drug, BGP-15, in insulin-resistant patients: a proof of concept randomized double-blind clinical trial","volume":"41","author":"Literati-Nagy","year":"2009","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.bbrc.2025.151498_bib154","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1478-3231.2010.02250.x","article-title":"The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients","volume":"30","author":"Gane","year":"2010","journal-title":"Liver Int."},{"key":"10.1016\/j.bbrc.2025.151498_bib155","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/j.cgh.2023.03.041","article-title":"Clinical trial landscape in NASH","volume":"21","author":"Harrison","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbrc.2025.151498_bib156","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/liv.15816","article-title":"Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH","volume":"44","author":"Alkhouri","year":"2024","journal-title":"Liver Int."},{"key":"10.1016\/j.bbrc.2025.151498_bib157","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1212\/WNL.0000000000207402","article-title":"Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial","volume":"101","author":"Karaa","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.bbrc.2025.151498_bib158","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jhep.2019.10.023","article-title":"Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase IIb study","volume":"72","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2025.151498_bib159","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2025.151498_bib160","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jhep.2023.02.004","article-title":"Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: a phase II randomized placebo-controlled trial (DESTINY-1)","volume":"78","author":"Harrison","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2025.151498_bib161","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25002128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25002128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T11:46:38Z","timestamp":1740743198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X25002128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":161,"alternative-id":["S0006291X25002128"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.151498","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mitochondrial targeted therapies in MAFLD","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.151498","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"151498"}}